[Form 4] Avalo Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Avalo Therapeutics insider stock option grant to Chief Business Officer — Boyd Taylor received a stock option on 10/01/2025

The option covers 275,000 shares of common stock with an exercise price of $12.96 and an expiration date of 10/01/2035. The award vests over four years: 25% vests on the first anniversary of the grant and the remainder vests in equal monthly installments over the next three years, subject to continued employment. Following the grant the reporting person beneficially owns 275,000 shares directly.

Positive

• 275,000‑share option grant ties executive pay to long‑term equity performance

Negative

• Potential dilution of 275,000 shares if options are exercised before expiration

Insights

Executive Compensation Analyst

Large multi‑year option aligns CBO incentives to long‑term performance.

The grant of $12.96 strike options for 275,000 shares vests over four years, creating a multi‑year retention mechanism for the Chief Business Officer. Such schedules encourage continued service while linking realized compensation to future share performance.

The award creates potential dilution equal to the optioned shares if exercised and depends on future stock price appreciation exceeding the exercise price. Monitor vesting anniversaries starting on 10/01/2026 and any subsequent exercises through the 10/01/2035 expiration for realized cost and dilution impact within the next 1–10 years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boyd Taylor

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.96	10/01/2025		A		275,000		(1)	10/01/2035	Common Stock	275,000	$0	275,000	D

Explanation of Responses:

1. The stock option was granted on October 1, 2025, and vests over four years, with the first 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments over the following three years, subject to the reporting person's continued employment with the Company on each applicable vesting date.

	/s/ Donald R. Reynolds, by Power of Attorney	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Boyd Taylor (AVTX) receive on 10/01/2025?

He received a stock option for 275,000 shares with an exercise price of $12.96 and an expiration date of 10/01/2035.

How does the option vest for Boyd Taylor (AVTX)?

The option vests over four years: 25% vests on the first anniversary of the grant date and the remainder vests in equal monthly installments over the following three years, subject to continued employment.

How many shares does Boyd Taylor beneficially own after the reported transaction?

Following the grant, the reporting person beneficially owns 275,000 shares directly as reported.

What is the exercise price and expiration for the derivative security?

The stock option has an exercise price of $12.96 and an expiration date of 10/01/2035.